Emerging Trends in New Psychoactive substance use: case study from the National Rehabilitation Center, Abu Dhabi United Arab Emirates

AUTORI

ABSTRACT

Introduction: New Psychoactive Substances (NPS), also known as designer or synthetic drugs, present significant challenges to public health. Defined as substances that produce altered states of consciousness they are not controlled by international drug treaties, at least when they initially enter the illicit market, NPS include synthetic cannabinoids, synthetic cathinones, stimulant-type drugs, and other emerging psychoactive substances. These drugs often mimic the effects of regulated substances but with varying and potentially severe health impacts. This article reviews the scope, classification, and clinical implications of NPS, focusing on their growing prevalence and the challenges they pose to healthcare systems, particularly in the United Arab Emirates (UAE) and in the broader Middle East region.
Methods: Specific case studies from the National Rehabilitation Center (NRC) in the UAE, illustrating the complexity of NPS-related health issues and the importance of advanced analytical techniques in detecting these substances, are also reported.
Results: Synthetic cannabinoids, such as MDMB-4en-PINACA and 5F-ADB, can lead to severe health issues, including metabolic disturbances and psychological effects. Synthetic cathinones, including 2,3-dimethylmethcathinone and naphyrone, have been associated with severe stimulant effects and health risks, as illustrated in the three cases reported.
Conclusion: Findings from the NRC underscore the increasing use of synthetic cannabinoids and cathinones in the region, highlighting the need for enhanced surveillance and treatment strategies. The role of comprehensive toxicological testing in managing substance use disorders are emphasized so as strategies for addressing the growing NPS epidemic. Through detailed case analyses and laboratory methodologies, this article contributes to the understanding of NPS and supports the development of effective public health responses.

BIBLIOGRAFIA

1. Collins H, eds .Collins English Dictionary. Legal highs. 13th edition. 2018
2. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). New psychoactive substances (NPS),
   euda.europa.eu/publications/european-drug-report. (last accessed: september 2024
3. United Nations Office on Drugs and Crime (UNODC) World Drug Report 2017 www.unodc.org/wdr2017/field/Booklet_1_EXSUM.pdf (last accessed: september 2024)
4. United Nations Office on Drugs and Crime (UNODC) World Drug Report 2016 www.unodc.org/doc/wdr2016/WORLD_DRUG_ REPORT_2016_web.pdf. (last accessed: september 2024)
5. Alhassan AEA. New Psychoactive Substances: chemical chameleons”that evade detection and legislations. Int J Emerg Ment Health Hum Resil 2017;9:1-4.
6. Yousif A New Psychoactive Substances (NPS): are we in times of a crisis or between crises? Int J Emerg Ment Health Hum Resil 2016;18: 1-2.
7. Alhassan A.E.A, , Elliott S, Venayikot M, Keller T. Synthetic cannabinoid detection in patients admitted for drug rehabilitation in the United Arab Emirates. Drug Test Anal 2024; doi: 10.1002/dta.3653. Epub ahead of print
8. Hill SL, Thomas SH. Clinical toxicology of newer recreational drugs. Clin Toxicol 2011;49:705-19.
9. United Nations Office on Drugs and Crime(UNODC) World Drug Report 2023. (www.unodc.org/unodc/en/data-and-analysis/world-drug-report-2023.html) (last accessed: october 2024)
10. Kasick, D. P., McKnight, C.A., Klisovic, E. “Bath salt” ingestion leading to severe intoxication delirium: two cases and a brief review of the emergence of mephedrone use. Am J Drug Alcohol Abuse 2012;38:176-80.
11. Kelly, J.P. Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test Anal 2011;3:439-53.
12. Manchester R,. Lomas EC, Waters L, Dempsey FC, Maskel P D. The emergence of new psychoactive substance (NPS) benzodiazepines: A review. Drug Test Anal 2018;10:37–53.
13. Tabarra I, Soares S, Rosado T, Gonçalves J, Luís Â, Malaca S, et al. Novel synthetic opioids – toxicological aspects and analysis. Forensic Sci Res 2019;4:111-40.
14. Pichini S, Pacifici R, Marinelli E, Busardò FP. European drug users at risk from illicit fentanyls mix. Front Pharmacol 2017;8:785.
15. Al Ghafri H, Abuelgasim EA, Ali AY, et al. A 6-year review of drug trends in the United Arab Emirates from the perspective of the National Rehabilitation Center (NRC) Abu Dhabi. Current Topics Toxicol 2020; 16:151-6.
16. Aldubayyan A A, Castrignanò E, Elliott S,Abbate V. A Quantitative LC–MS/MS method for the detection of 16 synthetic cathinones and 10 metabolites and its application to suspicious clinical and forensic urine samples. Pharmaceuticals (Basel). 2022;15:510.
17. Smith JP, Sutcliffe OB, Banks CE. An overview of recent developments in the analytical detection of new psychoactive substances (NPSs). Analyst 2015;140:4932-48.
18. Garg U, Hammett-Stabler C, eds. Clinical Applications of Mass Spectrometry: Methods and Protocols. Clifton, New Jersey (USA): Humana Press , 2010
19. Santos I.C, Maia D, Oliveira RJD, Barbosa D J. New Psychoactive Substances: Health and Legal Challenges. Psychoactives 2024; 3: 285-302;